Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Blood (2018) 132 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2018-99-117767

Published: 2018

Journal Articles

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Katie S Gatwood, PharmD, Kathryn A Culos, PharmD, Laura A Binari, MD, Brian G Engelhardt, MD, Adetola A. Kassim, MD MS, Michael Byrne, MD, Stacey A Goodman, MD MS, Wichai Chinratanalab, MD, Salyka M. Sengsayadeth, MD, John P. Greer, MD, Madan Jagasia, MD MBBS, MS, Bipin N. Savani, MD

Blood (2017) 130 (Supplement 1): 3210.

https://doi.org/10.1182/blood.V130.Suppl_1.3210.3210

Published: 2017

Journal Articles

Differential Impact of Signaling Inhibitor Treatment Versus Standard Chemoimmunotherapy on Chronic Lymphocytic Leukemia T Cells: Clinical Implications

Anna Vardi, MD PhD, Elisavet Vlachonikola, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Evangelia Stalika, Andreas Agathangelidis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Kostas Stamatopoulos, Anastasia Hadzidimitriou

Blood (2017) 130 (Supplement 1): 2999.

https://doi.org/10.1182/blood.V130.Suppl_1.2999.2999

Published: 2017

Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Blood (2016) 128 (22): 4382.

https://doi.org/10.1182/blood.V128.22.4382.4382

Published: 2016

Journal Articles

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Angela Gravetti, Giuseppe Monaco, Carolina Copia, Salvatore Palmieri, Fioravante Ronconi, Stefano Rocco, Felicetto Ferrara

Blood (2015) 126 (23): 5300.

https://doi.org/10.1182/blood.V126.23.5300.5300

Published: 2015

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Issa F. Khouri, Rima M Saliba, PhD, Celina Ledesma, Elias J. Jabbour, MD, Francesco Turturro, MD, Gheath Alatrash, DO, PhD, Sairah Ahmed, MD, Betul Oran, MD, Krina K Patel, Amanda Olson, David Marin, MD, Uday R. Popat, MD, Tina S Suki, Jeffrey L. Jorgensen, MD PhD, L. Jeffrey Medeiros, MD, Alison M Gulbis

Blood (2015) 126 (23): 2011.

https://doi.org/10.1182/blood.V126.23.2011.2011

Published: 2015

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Lukas Smolej, MDPhD, Yvona Brychtova, MD PhD, Michael Doubek, Prof., MD PhD, Eduard Cmunt, MDPhD, Martin Spacek, MD, PhD, David Belada, MD, Monika Motyckova, MDPhD, Irena Zygulova, MD, Dagmar Adamova, MD, Vit Prochazka, MDPhD, Martin Simkovic, MD, Katerina Klaskova, MS, Tomas Kozak, MDPhD

Blood (2014) 124 (21): 4670.

https://doi.org/10.1182/blood.V124.21.4670.4670

Published: 2014

Journal Articles

Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience

Blood (2014) 124 (21): 5655.

https://doi.org/10.1182/blood.V124.21.5655.5655

Published: 2014

Journal Articles

Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study

Yunsuk Choi, MD PhD, Jung-Hee Lee, MD PhD, Chul Won Jung, MD PhD, Jin Seok Kim, Inho Kim, MD PhD, Silvia Park, MD, June-Won Cheong, MD, PhD, Seonyang Park, MD PhD, Sung-Yong Kim, Mark Hong Lee, MD PhD

Blood (2014) 124 (21): 5669.

https://doi.org/10.1182/blood.V124.21.5669.5669

Published: 2014

Journal Articles

Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study

Luca Laurenti, MD, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Ghio, Nadia Cecconi, Vincenzo Pitini, Patrizia Mondello, Maria Rosa Lanza Cariccio, Alessandro Gozzetti, Giovanni D'Arena, Roberta Murru, MD, Nicola Piccirillo, Giuseppe Leone, MD, Simona Sica, MD

Blood (2013) 122 (21): 5309.

https://doi.org/10.1182/blood.V122.21.5309.5309

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

DNA Methylation Changes In Patients With Chronic Lymphocytic Leukemia Relapsing After Treatment Are Not Stochastic But Rather Selectively Affect Critical Pathways For B-Cell Physiology

Nikos Papakonstantinou, Andigoni Malousi, Maria Tsagiopoulou, Jana Gutwein, Ole Ammerpohl, Michael Kneba, MD, Achilles Anagnostopoulos, MD, Matthias Ritgen, MD, Nikos Maglaveras, Reiner Siebert, MD, Christiane Pott, M.D. Ph.D., Kostas Stamatopoulos

Blood (2013) 122 (21): 4146.

https://doi.org/10.1182/blood.V122.21.4146.4146

Published: 2013

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Young Kwang Chae, MD, MPH, Long Xuan Trinh, Michael J. Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 2904.

https://doi.org/10.1182/blood.V120.21.2904.2904

Published: 2012

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)

Petra Obrtlikova, MD, Anna Jonasova, MD, Magda Siskova, MD, Eduard Cmunt, MD, Adela Berkova, MD, Josef Karban, MD, Katerina Svackova, Marek Trneny, MD

Blood (2012) 120 (21): 1790.

https://doi.org/10.1182/blood.V120.21.1790.1790

Published: 2012

Journal Articles

The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen

Anna Panovska, MD, Daniel Lysák, MD, Lukas Smolej, M.D., Ph.D., Yvona Brychtova, M.D., Ph.D., Martin Simkovic, MD, Monika Motyckova, M.D., Michaela Lindtnerova, MD, Martin Trbusek, PhD, Jitka Malcikova, Dr, PhD, Sarka Pospisilova, Prof., Jiri Mayer, M.D., PhD., Prof., Michael Doubek, M.D., PhD., Prof.

Blood (2012) 120 (21): 4603.

https://doi.org/10.1182/blood.V120.21.4603.4603

Published: 2012

Journal Articles

Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Kirsten Fischer, MD, Jasmin Bahlo, Anna- Maria Fink, MD, Raymonde Busch, Sebastian Böttcher, MD, Jiri Mayer, MD, Peter Dreger, MD, Christian Maurer, Anja Engelke, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2012) 120 (21): 435.

https://doi.org/10.1182/blood.V120.21.435.435

Published: 2012

Journal Articles

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial

Stephane Lepretre, Therese Aurran, Beatrice Mahé, Bruno Cazin, Olivier Tournilhac, Herve Maisonneuve, Olivier Casasnovas, Alain Delmer, Veronique Leblond, Bruno Royer, Bernadette Corront, Sylvie Chevret, Roselyne Delépine, Sandrine Vaudaux, Eric Van Den Neste, Marie Christine Béné, Remi Letestu, Florence Cymbalista, Pierre Feugier

Blood (2012) 119 (22): 5104–5110.

https://doi.org/10.1182/blood-2011-07-365437

Published: 2012

NARROW

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Differential Impact of Signaling Inhibitor Treatment Versus Standard Chemoimmunotherapy on Chronic Lymphocytic Leukemia T Cells: Clinical Implications

FCR for Advanced Chronic Lymphocytic Leukemia: Real Life Results from a Series of 50 Patients Treated at a Single Institution

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience

Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study

Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

DNA Methylation Changes In Patients With Chronic Lymphocytic Leukemia Relapsing After Treatment Are Not Stochastic But Rather Selectively Affect Critical Pathways For B-Cell Physiology

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)

The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only